1)Hur C, Miller M, Kong CY, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer 119:1149-1158, 2013
2)Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 95:142-146, 2005
3)Lagergren J, Lagergren P. Recent developments in esophageal adenocarcinoma. CA Cancer J Clin 63:232-248, 2013
4)Tachimori Y, Ozawa S, Numasaki H, et al. Comprehensive Registry of Esophageal Cancer in Japan, 2009. Esophagus 13:110-137, 2016
5)Sikkema M, de Jonge PJ, Steyerberg EW, et al. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus:a systematic review and meta-analysis. Clin Gastroenterol Hepatol 8:235-244, 2010
6)Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus:a meta-analysis. Gut 61:970-976, 2012
7)Amano Y, Kinoshita Y. Barrett esophagus:perspective on its diagnosis and management in Asian populations(NY). Gastroenterol Hepatol 4:45-53, 2008
8)Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus:the Practice Parameters Committee of the Amerian College of Gastroenterology. Am J Gastroenterol. 93:1028-1032, 1998
9)Evans JA, Early DS, Fukami N, et al. The role of endoscopy in Barrett's esophagus and other premalignant conditions of the esophagus. Gastrointest Endosc 76:1087-1094, 2012
10)Abrams JA, Kapel RC, Lindberg GH, et al. Adherence to biopsy guidelines for Barrett's esophagus surveillance in community setting in the United States. Clin Gastroenterol Hepatol 7:736-742, 2009
11)Kobayashi M, Takeuchi M, Ajioka Y, et al. Mucin phenotype and narrow-band imaging with magnifying endoscopy for differentiated-type mucosal gastric cancer. J Gastroenterol 46:1064-1070, 2011
12)Goda K, Singh R, Oda I, et al. Current status of endoscopic diagnosis and treatment of superficial Barrett's adenocarcinoma in Asia-Pacific region. Dig Endosc 25(Suppl 2):146-150, 2013